|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-7-22
|
|
pubmed:abstractText |
Our previous data have shown a significantly higher tumor response to anti-CD3/anti-Pgp bispecific diabody-mediated immunotherapy for P-glycoprotein (Pgp)-overexpressing K562/A02 cells, but a rapid tumor relapse occurred at 1 week after therapy. In an attempt to overcome tumor recurrence, we supplemented the previous therapy with extracellular domain of human 4-1BBL (ex4-1BBL) to regulate the activation of peripheral blood lymphocyte (PBL). As a result, this combination showed enhanced cytotoxicity in vitro and eradicated the multidrug-resistant xenografts of K562/A02 in nude mice. Furthermore, no tumor recurrence was observed within 100 days after the first treatment. Therefore, when used as an adjuvant, ex4-1BBL may improve the outcome of PBL-based immunotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/4-1BB Ligand,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Bispecific,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD137,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/TNFRSF9 protein, human
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1090-2163
|
|
pubmed:author |
pubmed-author:ChengXinX,
pubmed-author:GaoYingdaiY,
pubmed-author:GuoHongxingH,
pubmed-author:JiangWenguoW,
pubmed-author:LiuWengeW,
pubmed-author:QiJingJ,
pubmed-author:WangJinhongJ,
pubmed-author:XiongDongshengD,
pubmed-author:YangChunzhengC,
pubmed-author:YangMingM,
pubmed-author:ZhouYuanY,
pubmed-author:ZhuZhenpingZ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
251
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
102-8
|
|
pubmed:meshHeading |
pubmed-meshheading:18482719-4-1BB Ligand,
pubmed-meshheading:18482719-Animals,
pubmed-meshheading:18482719-Antibodies, Bispecific,
pubmed-meshheading:18482719-Antigens, CD137,
pubmed-meshheading:18482719-Antigens, CD3,
pubmed-meshheading:18482719-Cell Proliferation,
pubmed-meshheading:18482719-Drug Resistance, Neoplasm,
pubmed-meshheading:18482719-Female,
pubmed-meshheading:18482719-Humans,
pubmed-meshheading:18482719-Immunotherapy,
pubmed-meshheading:18482719-Interleukin-2,
pubmed-meshheading:18482719-Jurkat Cells,
pubmed-meshheading:18482719-K562 Cells,
pubmed-meshheading:18482719-Leukemia,
pubmed-meshheading:18482719-Lymphocytes,
pubmed-meshheading:18482719-Mice,
pubmed-meshheading:18482719-Mice, Inbred BALB C,
pubmed-meshheading:18482719-Mice, Nude,
pubmed-meshheading:18482719-P-Glycoprotein,
pubmed-meshheading:18482719-Protein Structure, Tertiary,
pubmed-meshheading:18482719-Random Allocation,
pubmed-meshheading:18482719-Specific Pathogen-Free Organisms,
pubmed-meshheading:18482719-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia.
|
|
pubmed:affiliation |
State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Science, Peking Union Medical College, Tianjin, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
